Novel trityl linked drug immunoconjugates for cancer therapy

Trityl linkers were utilized in the preparation of acid labile nucleoside monoclonal antibody conjugates, COL1-N6-Trityl-207702 (1a-f). Conjugation led to high levels of drug incorporation into the MoAb with retention of good immunoreactivity. A strong correlation was found between the cytotoxicity of the constructs and substituents R and R′ on the aromatic rings of the trityl linker.